Entheon Acquires Mentis AI: A Game Changer for Mental Health and Wellness

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) has announced a significant strategic move with the acquisition of Mentis AI, a private R&D company specializing in AI technologies for mental health and loneliness solutions. This acquisition will provide Entheon with AI companions and coaching tools, enhancing their existing HaluGen's Psychedelics and Lobo's Cannabis Genetic Test Kit services. The transaction is expected to close by February 28, 2025, subject to due diligence, definitive agreement execution, and regulatory approvals.

The acquisition of Mentis AI will allow Entheon to gain a broader and more detailed understanding of its customers, including their health information, mindset, experience data, measure of outcome, and quality-of-life improvements. This enhanced understanding will enable Entheon to create robust and meaningful relationships with customers, better serving their needs and challenges in mental health and wellness journeys. Timothy Ko, CEO of Entheon, stated, "What the AI assets and expertise of Mentis AI represent for the company is an increased ability for us to create robust and meaningful relationships with customers and to understand their needs, their challenges, and how we can better serve them in their mental health and wellness journeys."

The transaction will be structured as a share exchange, with Mentis AI shareholders receiving 12.84296 Entheon shares for each Mentis AI share held. This will result in approximately 11 million Entheon shares being issued to Mentis AI shareholders, representing approximately 44.25% of the issued and outstanding Entheon shares post-transaction.

The integration of AI technologies from Mentis AI is of immediate use to Entheon's existing platforms and opens up the potential to explore a broadening of services and products offered by Entheon. This expansion can facilitate positive changes in the lives of those seeking change and drive growth and innovation for the company.

In conclusion, the acquisition of Mentis AI by Entheon Biomedical Corp. is a strategic move that will enhance the company's existing platforms and services, create new opportunities for growth and innovation, and ultimately improve the lives of those seeking mental health and wellness solutions. By leveraging the AI assets and expertise of Mentis AI, Entheon can better understand and serve its customers, create long-form relationships, and explore new markets. This acquisition is a testament to Entheon's commitment to driving positive changes in the lives of those who seek change.